Solventum: Q4 EPS Beats, Cash Flow Dips
Solventum surpassed fourth-quarter revenue and earnings expectations while facing challenges in segments and regulatory ...
Nelson Peltz’s Trian Pushes Solventum to Further Simplify Business
Activist investor Trian Fund Management plans to push Solventum to separate more of its businesses after the company’s $4.1 ...
Solventum price target raised to $75 from $73 at Wells Fargo
Wells Fargo raised the firm’s price target on Solventum (SOLV) to $75 from $73 and keeps an Equal Weight rating on the shares. The Q4 beat was ...
MassDevice5h
Solventum beats The Street in Q4
Solventum (NYSE:SOLV) yesterday announced fourth-quarter results that came in ahead of the consensus forecast on Wall Street.
Solventum forecasts annual profit above estimates on strong surgical product sales
M spin-off Solventum forecast annual profit above analyst estimates on Thursday, betting on strong sales of its wound care and surgical sterilization products.
Solventum price target raised to $84 from $75 at Piper Sandler
Piper Sandler raised the firm’s price target on Solventum (SOLV) to $84 from $75 and keeps a Neutral rating on the shares. The firm notes ...
Solventum In The Early Stages Of A Multiyear Turnaround Effort
Solventum faces significant challenges in its turnaround, including slow-growing core businesses, share loss, and margin ...
Solventum Corp (SOLV) Q4 2024 Earnings Call Highlights: Strong EPS and Strategic Moves Amid ...
Solventum Corp (SOLV) reports robust earnings per share and strategic advancements, while navigating separation complexities and market headwinds.
Stifel Nicolaus Remains a Buy on Solventum Corporation (SOLV)
Stifel Nicolaus analyst Rick Wise maintained a Buy rating on Solventum Corporation (SOLV – Research Report) today and set a price target of ...